C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk

Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2009-06, Vol.100 (12), p.1846-1851
Main Authors: EKLUND, C. M, TAMMELA, Tlj, SCHLEUTKER, J, HURME, M
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Biomarkers, Tumor - blood
Bone Neoplasms - blood
Bone Neoplasms - genetics
Bone Neoplasms - secondary
C-Reactive Protein - genetics
C-Reactive Protein - metabolism
Case-Control Studies
Clinical Study
Genome-Wide Association Study
Genotype
Haplotypes - genetics
Humans
Male
Medical sciences
Middle Aged
Neoplasm Staging
Nephrology. Urinary tract diseases
Polymorphism, Single Nucleotide - genetics
Prognosis
Prostate-Specific Antigen - blood
Prostate-Specific Antigen - genetics
Prostatic Neoplasms - blood
Prostatic Neoplasms - genetics
Prostatic Neoplasms - pathology
Risk Factors
Survival Rate
Treatment Outcome
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Growing evidence points to a role for inflammation in prostate carcinogenesis. The significance of C-reactive protein (CRP), an inflammatory and innate immunity molecule, has not been evaluated thoroughly in prostate cancer (PC). In this study of 739 Finnish patients with PC and 760 healthy men, we evaluated the associations of CRP genotypes and haplotypes with total PC risk and PC progression, using prostate-specific antigen (PSA) as a marker of metastatic disease. Although the haplotype frequencies were similar in patients and controls, an association between haplotype ACCCA and patients' PSA levels was found. The carriers more often had a high PSA than non-carriers (P=0.0002) and the SNP rs2794521 A-allele and rs1800947 C-allele carriers had a higher PSA than non-carriers (P=0.009 and P=0.0004, respectively). A trend for a younger age at diagnosis was found among the carriers of ACCCA (P=0.07) and the rs1800947 C-allele (P=0.06), as well as a trend for the latter to have more likely metastases (P=0.06), but not after Bonferroni correction (alpha=0.00208). This is the first study to suggest association between PSA and CRP variants in PC and, therefore, further studies are warranted. CRP alleles previously found to protect against increased CRP levels are now suggested to be associated with metastatic PC, indicated by elevated PSA.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605081